46252 Federal Register / Vol. 82, No. 191 / Wednesday, October 4, 2017 / Notices 

any institution employing her shall 

submit, in conjunction with each 

application for PHS funds, or report, 

manuscript, or abstract involving PHSsupported research in which 

Respondent is involved, a certification 

to ORI that the data provided by 

Respondent are based on actual 

experiments or are otherwise 

legitimately derived and that the data, 

procedures, and methodology are 

accurately reported in the application, 

report, manuscript, or abstract; 

(3) to exclude herself voluntarily from 

serving in any advisory capacity to PHS 

including, but not limited to, service on 

any PHS advisory committee, board, 

and/or peer review committee, or as a 

consultant for a period of three (3) years, 

beginning with the effective date of the 

Agreement; and 

(4) that as a condition of the 

Agreement, Respondent will request 

that PLoS One 8(8):e71868, 2013 be 

corrected or retracted. 

FOR FURTHER INFORMATION CONTACT: 

Director, Office of Research Integrity, 

1101 Wootton Parkway, Suite 750, 

Rockville, MD 20852, (240) 453–8200. 

Kathryn M. Partin, 

Director, Office of Research Integrity. 

[FR Doc. 2017–21367 Filed 10–3–17; 8:45 am] 

BILLING CODE 4150–31–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Human Genome Research 

Institute; Notice of Closed Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Human 

Genome Research Institute Special Emphasis 

Panel, SEP U24 Research Resource. 

Date: November 30, 2017. 

Time: 11:00 a.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Human Genome Research 

Institute, 5635 Fishers Lane, Suite 3146, 

Rockville, MD 20852 (Telephone Conference 

Call). 

Contact Person: Rudy O. Pozzatti, Ph.D., 

Scientific Review Officer, Scientific Review 

Branch, National Human Genome Research 

Institute, 5635 Fishers Lane, Suite 4076, MSC 

9306, Rockville, MD 20852, (301) 402–0838, 

pozzattr@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.172, Human Genome 

Research, National Institutes of Health, HHS) 

Dated: September 28, 2017. 

Sylvia L. Neal, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2017–21263 Filed 10–3–17; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; Multisite Clinical Trials. 

Date: October 19, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, (Telephone 

Conference Call). 

Contact Person: Shang-Yi Anne Tsai, 

Ph.D., Scientific Review Officer, Office of 

Extramural Policy and Review, Division of 

Extramural Research, National Institute on 

Drug Abuse, NIH, DHHS, 6001 Executive 

Boulevard, Room 4228, MSC 9550, Bethesda, 

MD 20892, 301–827–5842, shangyi.tsai@

nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIDA 

Mentored Clinical Scientists Development 

Program Award in Drug Abuse and 

Addiction (K12). 

Date: October 25, 2017. 

Time: 9:00 a.m. to 12:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: Susan O. McGuire, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Blvd., 

Room 4245, Rockville, MD 20852, (301) 827– 

5817, mcguireso@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; NIH 

Pathway to Independence Award (K99/R00). 

Date: October 25, 2017. 

Time: 1:00 p.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: Susan O. McGuire, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Blvd., 

Room 4245, Rockville, MD 20852, (301) 827– 

5817, mcguireso@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; (T32) 

Ruth L. Kirschstein National Research 

Service Award (NRSA) Institutional Research 

Training Grants. 

Date: October 26–27, 2017. 

Time: 8:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852. 

Contact Person: Susan O. McGuire, Ph.D. 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Blvd., 

Room 4245, Rockville, MD 20852, (301) 827– 

5817, mcguireso@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Exploring Novel RNA Modifications in HIV/ 

AIDS and Substance Use Disorders (R01, 

R21). 

Date: November 1, 2017. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852, 

Contact Person: Susan O. McGuire, Ph.D., 

Scientific Review Officer, Office of 

Extramural Policy and Review, National 

Institute on Drug Abuse, National Institutes 

of Health, DHHS, 6001 Executive Blvd., 

Room 4245, Rockville, MD 20852, (301) 827– 

5817, mcguireso@mail.nih.gov. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; CuttingEdge Basic Research Awards (CEBRA) (R21). 

Date: November 29, 2017. 

Time: 9:00 a.m. to 5:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: Bethesda North Marriott Hotel & 

Conference Center, 5701 Marinelli Road, 

Bethesda, MD 20852. 


sradovich on DSK3GMQ082PROD with NOTICES